The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Myeloma XI: early treatment stratification and novel treatment approaches
Martin Kaiser, MD, Royal Marsden NHS Foundation Trust, London, UK, discusses the Myeloma XI trial (NCT01554852) and stresses the urgent need for improved treatment approaches for ultra-high-risk patients with multiple myeloma, as delay can mean that they receive only modest benefit from therapies beyond second line. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
